" class="no-js "lang="en-US"> Daniel Skovronsky - Medtech Alert
Saturday, September 23, 2023
Daniel Skovronsky

Daniel Skovronsky

About Daniel Skovronsky

As President of Lilly Research Labs and Senior Vice President of Science and Technology at Eli Lilly and Company, Dan is responsible for developing the Lilly pipeline of molecules and speeding innovative medicines to patients. He previously was the Senior Vice President, Clinical and Product Development at Lilly.

Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals, a company that Dan founded in 2004 and subsequently served as President and CEO. At Avid, Dan led the discovery, development, and FDA approval of Amyvid®, the first diagnostic agent for brain imaging of beta-amyloid plaques in patients with cognitive impairment being evaluated for Alzheimer’s disease and other causes of cognitive decline. He currently serves as chairman of Avid.

Dan trained as a resident in pathology and completed a fellowship in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. and Ph.D. from the University of Pennsylvania and did his undergraduate training in molecular biophysics and biochemistry at Yale University.

Related Story

Lilly, Vir, GSK Announce Positive Topline Data from Phase 2 BLAZE-4 Trial

March 30 2021

Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced […]